---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Heterogeneity of treatment effect"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Heterogeneity of treatment effect. Topics: HLA-A∗02:01 status: confirmed response in first-line and any-line participants of OptimUM-01, August 2023; HLA-A∗02:01 status: sponsor summary of first-line activity in the pooled OptimUM-01 population; Line of therapy and hepatic-only disease: OptimUM-01 per-protocol efficacy population, March 2023 data cutoff; MET pathway activity and response to darovasertib monotherapy; 13 further topics. 17 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### HLA-A∗02:01 status: confirmed response in first-line and any-line participants of OptimUM-01, August 2023

> “Clinical efficacy was observed in both human leukocyte antigen (HLA)-A2 positive (HLA-A2(+)) and HLA-A2 negative (HLA-A2(-)) patients.”
> “There were 50 all-line MUM patients with known HLA-A2 status among the 63 patients evaluable for efficacy, with 31 of these being HLA-A2(-) and 19 being HLA-A2(+).”
> “For HLA-A2(-) MUM patients, confirmed PRs were observed in 9 of 31 (29% overall response rate (ORR)) any-line and in 5 of 12 (42% ORR) first-line patients.”
> “For HLA-A2(+) MUM patients, confirmed PRs were also observed in 6 of 19 (32% ORR) any-line and in 3 of 5 (60% ORR) first-line patients.”

Source: [IDEAYA Biosciences press release, ESMO 2023 phase 2 results (2023)](https://media.ideayabio.com/2023-10-23-IDEAYA-Announces-Top-Line-Phase-2-Results-at-ESMO-2023-of-Darovasertib-and-Crizotinib-Combo-in-MUM,-and-Clinical-Efficacy-Updates-for-Neoadjuvant-UM,-GNAQ-11-Cutaneous-Melanoma,-and-Synthetic-Lethality-Pipeline)

<a id="topic-2.2.2.3-2"></a>

### HLA-A∗02:01 status: sponsor summary of first-line activity in the pooled OptimUM-01 population

> “Strong Clinical Activity in First-line Patients Regardless of HLA-A*02:01 Status”
> “Darovasertib plus crizotinib demonstrated durable outcomes in a pooled first-line population that included both HLA-A*02:01-positive and HLA-A*02:01-negative patients (n=44)”

Source: [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf)

<a id="topic-2.2.2.3-3"></a>

### Line of therapy and hepatic-only disease: OptimUM-01 per-protocol efficacy population, March 2023 data cutoff

> “In the PPEP, 30% had a confirmed partial response (cPR) with 92% of patients having tumor shrinkage.”
> “First-line (1L) pts (n=20) had a cPR of 45% with 95% of patients having tumor shrinkage.”
> “Median PFS (mPFS) in both PPEP and 1L pts was ∼7 months.”
> “In pts with hepatic only disease (n=20 pts, 1L and pretreated), an ORR of 35% and mPFS was 11 months.”

Source: [McKean et al. (2023)](https://www.annalsofoncology.org/article/S0923-7534%2823%2903052-1/fulltext)

<a id="topic-2.2.2.3-4"></a>

### MET pathway activity and response to darovasertib monotherapy

> “These data also validate the company's translational research discovery that Phase 1 clinical response to darovasertib monotherapy associated with low cMETactivity, as measured by gene signature score.”

Source: [IDEAYA Biosciences press release, phase 2 expansion dose data in pretreated metastatic uveal melanoma (2021)](https://media.ideayabio.com/2021-12-07-IDEAYA-Reports-Clinical-Data-from-Phase-2-Expansion-Dose-of-Darovasertib-and-Crizotinib-Synthetic-Lethal-Combination-in-Heavily-Pre-Treated-Metastatic-Uveal-Melanoma)

<a id="topic-2.2.2.3-5"></a>

### GNAQ and GNA11 mutations as the shared target population of PKC inhibition

> “Uveal melanoma (UM) is a rare, aggressive form of ocular cancer in which approximately 95% of patients have activating mutations in GNAQ/11 GTPase proteins that drive downstream PKC signaling and tumor growth.”

Source: [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma)

<a id="topic-2.2.2.3-6"></a>

### Tebentafusp: overall survival in prespecified and exploratory subgroups with extended follow-up

> “Tebentafusp improved survival even in poor-prognosis groups, such as patients with baseline tumors ≥10 cm or those whose best RECISTv1.1 response was progressive disease, including cases where target tumor growth exceeded 20%.”
> “The treatment effect persisted across most prespecified subgroups with extended follow-up (Figure 2A).”
> “Additional exploratory subgroup analyses also showed a survival advantage associated with tebentafusp regardless of metastasis location (hepatic only or hepatic and extrahepatic) or baseline tumor burden, as measured by the sum of target lesion diameters (Figure 2B).”

Source: [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext)

<a id="topic-2.2.2.3-7"></a>

### Tebentafusp: baseline factors associated with longer overall survival and with survival of at least 5 years

> “The baseline factors that were most associated with longer overall survival during treatment with tebentafusp included an ECOG performance-status score of 0, levels of LDH and alkaline phosphatase in the normal range, a largest metastatic lesion that was less than 8 cm in diameter, and a longer time since primary diagnosis (Table S5).”

Source: [Hassel et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11188986/)

> “Accordingly, although tebentafusp-treated patients who survived at least 5 years included a mix of ages, genders, and tumor locations, all but one were ECOG 0 at baseline and typically presented with normal LDH and alkaline phosphatase levels as well as small metastatic lesions”

Source: [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext)

<a id="topic-2.2.2.3-8"></a>

### Tebentafusp: disease volume and line of therapy as modifiers of benefit in expert discussion

> “Disease volume and line of therapy were identified as underrecognized modifiers of tebentafusp benefit, with faculty reporting better responses in frontline, lower-volume disease.”
> “This is consistent with trial data showing stronger responses in patients with liver lesions smaller than 3 cm and minimal benefit in heavily pretreated, high-volume settings.”

Source: [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape)

<a id="topic-2.2.2.3-9"></a>

### Tebentafusp: circulating tumor DNA reduction at week 9 and overall survival, 3-year analysis

> “In an exploratory analysis, 202 of the 252 patients in the tebentafusp group had baseline and week 9 serum samples that were obtained during treatment and were available for ctDNA analysis; 123 of the patients with a sample (61%) had at least one detectable uveal mutation at baseline.”
> “Likewise, patients who had clearance of ctDNA by week 9 had longer overall survival than those without clearance (median overall survival, 29.6 months vs. 10.2 months) (Fig. 3B).”
> “Overall survival among the 99 patients who had a reduction of at least 50% in the ctDNA level was longer than that among the 24 patients who had a reduction of less than 50%, no change, or an increase in the ctDNA level (hazard ratio for death, 0.41; 95% CI, 0.25 to 0.67) (Fig. 3C).”

Source: [Hassel et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11188986/)

<a id="topic-2.2.2.3-10"></a>

### Tebentafusp: circulating tumor DNA reduction by best response and baseline tumor burden, 5-year analysis

> “Nearly half of evaluable patients with progressive disease (35 of 73 [48%]) experienced at least a 50% reduction in ctDNA levels, and 20 (27%) achieved complete ctDNA clearance (Table 1).”
> “A ctDNA reduction of 50% or greater occurred in 9 of 12 (75%) patients with baseline tumor size ≥8.1 cm, 43 of 53 (81%) with tumors of 3.1 to 8.0 cm, and 47 of 58 (81%) with tumors of ≤3.0 cm.”
> “Patients with undetectable baseline ctDNA had a median and estimated 5-year overall survival of 27.3 months (95% CI 24.1-34.3) and 27% (95% CI 17-38), similar to those who cleared ctDNA by week 9 [median 29.6 (95% CI 23-37) months and 19% (95% CI 9-33) at 5 years; Figure 3A and B].”

Source: [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext)

<a id="topic-2.2.2.3-11"></a>

### Tebentafusp: BAP1 loss in the control group

> “Furthermore, in an exploratory analysis of a subset of patients with available tumor sequencing data, any loss of BAP1 was associated with a trend toward shorter overall survival in the control group compared to those with wild-type BAP1”

Source: [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext)

<a id="topic-2.2.2.3-12"></a>

### Tebentafusp: early rash as a predictor of overall survival

> “rash within 1 week was not an independent predictor of overall survival”

Source: [Hassel et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11188986/)

> “Although the development of early cutaneous toxicity has repeatedly been linked to better survival outcomes, this relationship does not appear to be independent of established prognostic variables.”

Source: [Koumprentziotis et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13664555/)

<a id="topic-2.2.2.3-13"></a>

### Immune checkpoint inhibitors: MBD4-deficient hypermutated tumors

> “Here we present a metastatic uveal melanoma patient with an exceptional high sensitivity to a PD-1 inhibitor associated with outlier CpG>TpG mutation burden, MBD4 germline deleterious mutation, and somatic MBD4 inactivation in the tumor.”
> “In our series of 42 metastatic UM patients treated with PD1inh, only one (UVM_IC) achieved a tumor response (details in Methods)”

Source: [Rodrigues et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5951831/)

> “Among the 12 patients who received ICIs, nine received pembrolizumab, two ipilimumab plus nivolumab followed by nivolumab, and one pembrolizumab plus lenvatinib within the frame of the PLUME phase 2 trial (NCT05282901).”
> “The overall response rate was 50% (two complete, four partial) with a disease control rate of 83%.”
> “At 12 months, 73% of patients were progression free, and the estimated 2-year OS was 86%.”
> “Our findings support further evaluation of MBD4 mutation as a predictive biomarker and suggest that ICIs should be considered as a preferred first-line option in MBD4-mutated mUM.”

Source: [Honoré et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13641210/)

<a id="topic-2.2.2.3-14"></a>

### Immune checkpoint inhibitors: low tumor mutational burden in GNAQ- or GNA11-mutant tumors

> “In addition, GNAQ/11 mutation patients are known to have low tumor mutational burden making these patients less likely to benefit from immune checkpoint inhibitor therapies.”

Source: [IDEAYA Biosciences press release, ESMO 2023 phase 2 results (2023)](https://media.ideayabio.com/2023-10-23-IDEAYA-Announces-Top-Line-Phase-2-Results-at-ESMO-2023-of-Darovasertib-and-Crizotinib-Combo-in-MUM,-and-Clinical-Efficacy-Updates-for-Neoadjuvant-UM,-GNAQ-11-Cutaneous-Melanoma,-and-Synthetic-Lethality-Pipeline)

> “Lack of mutation burden and T cell infiltration, and MYC overexpression may be factors limiting therapeutic responses.”

Source: [Johnson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8063157/)

<a id="topic-2.2.2.3-15"></a>

### Immune checkpoint inhibitors: liver metastasis volume and extrahepatic-only disease

> “Notably, the patients who benefited either had no liver metastases or small volume disease whereas rapidly progressing patients had bulky liver involvement.”

Source: [Johnson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8063157/)

> “(A) PFS for patients with extrahepatic-only sites of metastases versus liver metastases was 12.0 months versus 5.5 months (P = .0918).”
> “Twenty-seven evaluable patients had liver metastases, of whom five (19%) had a PR and three (11%) had stable disease for 6 months or longer.”

Source: [Pelster et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8257877/)

> “Patients with extrahepatic metastases only and treated with ipilimumab-nivolumab combination seem to have a better prognostic, the expected survival was 3.2 times higher than with any other systemic treatment (HR 0.28, 95% CI: 0.11–0.69).”

Source: [Piperno-Neumann et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12962742/)

<a id="topic-2.2.2.3-16"></a>

### Immune checkpoint inhibitors: lactate dehydrogenase level and outcomes

> “Normal LDH was associated with improved OS (p=0.026)”
> “However, elevated LDH was not associated with significantly worse PFS.”

Source: [Najjar et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7319717/)

> “PFS was influenced by higher LDH values.”

Source: [Piulats et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33417511/)

<a id="topic-2.2.2.3-17"></a>

### Lactate dehydrogenase and alkaline phosphatase as prognostic factors in the guideline

> “Elevated lactate dehydrogenase and alkaline phosphatase levels were the most significant prognostic factors for 6-month PFS and 1-year OS rates in a multivariate analysis.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
